Hemoglobin infusion augments the tumor necrosis factor response to bacterial endotoxin (lipopolysaccharide) in mice
- 1 April 1999
- journal article
- research article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 27 (4) , 771-778
- https://doi.org/10.1097/00003246-199904000-00034
Abstract
To determine whether cell-free hemoglobin augments the inflammatory cascade, as detected by production of tumor necrosis factor (TNF) elicited by bacterial endotoxin (lipopolysaccharide [LPS]). In vivo and ex vivo study, using a mouse model of sepsis. Animal research facility Female Swiss Webster mice For the in vivo experiments, an LD50 dose (500 [micro sign]g) of Escherichia coli LPS was injected intraperitoneally into mice. Cell-free crosslinked hemoglobin (60 mg/mouse) or saline was administered intravenously 10 hrs before or coincident with LPS. For the ex vivo experiments, hemoglobin (60 mg/mouse) or saline was administered intravenously to mice, and, 10 hrs later, hepatic Kupffer cells, peripheral blood mononuclear cells, or peritoneal macrophages were isolated. Intravenous infusion of hemoglobin either 10 hrs before or coincident with intraperitoneal LPS resulted in a peak of plasma TNF that was greater than in control mice administered LPS only. Cultured Kupffer cells, isolated from mice that had received hemoglobin in vivo 10 hrs before cell collection, produced more TNF in response to LPS in vitro than cells from normal mice. A trend toward greater TNF production in vitro by peripheral blood mononuclear cells obtained from hemoglobin-treated mice also was observed. Enhanced sensitivity to LPS was not observed with cultured peritoneal macrophages from mice that had received hemoglobin. Intravenous hemoglobin increased the sensitivity of hepatic macrophages to subsequent stimulation by LPS. This effect may contribute to the increased mortality that we have observed in animals that have received both LPS and hemoglobin. (Crit Care Med 1999; 27:771-778)Keywords
This publication has 32 references indexed in Scilit:
- Haemoglobin‐Based Red Cell Substitutes: Current StatusVox Sanguinis, 1995
- The importance of a lipopolysaccharide-initiated, cytokine-mediated host defense mechanism in mice against extraintestinally invasive Escherichia coli.Journal of Clinical Investigation, 1995
- Red blood cell substitutes: current statusBritish Journal of Anaesthesia, 1995
- Haemoglobin-based blood substitutes and sepsisThe Lancet, 1995
- Human hemoglobin increases the biological activity of bacterial lipopolysaccharides in activation of Limulus amebocyte lysate and stimulation of tissue factor production by endothelial cells in vitroInnate Immunity, 1994
- Production of modified crosslinked cell‐free hemoglobin for human use: the role of quantitative determination of endotoxin contaminationTransfusion, 1993
- Interleukin 10 reduces the release of tumor necrosis factor and prevents lethality in experimental endotoxemia.The Journal of Experimental Medicine, 1993
- Role for monokines in the metabolic effects of endotoxin. Interferon-gamma restores responsiveness of C3H/HeJ mice in vivo.Journal of Clinical Investigation, 1992
- Sepsis SyndromeInfectious Disease Clinics of North America, 1991
- Synergistic Toxicity of Gram-negative Bacteria and Free Colloidal HemoglobinAnnals of Surgery, 1963